Article
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.
British journal of cancer - 16 Feb 2010
Smith G, Bounds R, Wolf H, Steele R J C, Carey F A, Wolf C R
Abstract excerpt
BACKGROUND: Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status. Current mandatory mutation testing for patient selection is limited to the K-Ras 'hotspot' codons 12 and 13. METHODS: Colorectal tumours (n=106)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
